Application of demethylwedelolactone to preparation of medicine for resisting pulmonary fibrosis

A technology of norwedelide and pulmonary fibrosis, which is applied in drug combinations and respiratory diseases, etc., can solve the problem that there are no literature reports on the application of wedelolide, the ineffective effect of pulmonary fibrosis, and the inability to finally slow down or terminate lung tissue, etc. Problems, to achieve a wide range of practical value, improve the degree of pulmonary fibrosis, the effect of low cost

Inactive Publication Date: 2016-06-22
张朝凤
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The general treatment of emphysema drugs is ineffective or poor in the treatment of pulmonary fibrosis, because the drugs that relax the bronchi cannot finally slow down or stop the excessive deposition of collagen in the lung tissue, and collagen deposition is the main feature of pulmonary fibrosis and etiology
[0004] At present, there is no literature report that wedelolide has the efficacy of treating pulmonary fibrosis and its application in the treatment of pulmonary fibrosis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of demethylwedelolactone to preparation of medicine for resisting pulmonary fibrosis
  • Application of demethylwedelolactone to preparation of medicine for resisting pulmonary fibrosis
  • Application of demethylwedelolactone to preparation of medicine for resisting pulmonary fibrosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0025] 1. Preparation and structure confirmation of norwedelide

[0026]The medicinal material of Eclipta prostrate is the dry aerial part of Eclipta prostrate L., a plant of Compositae, which was purchased from Bozhou, Anhui. Reagents such as ethanol and petroleum ether were of analytical grade. Dry the aboveground part of Eclipta chinensis, extract 3 times with 80% ethanol 10 times the volume of crude drug, 2 hours each time, filter, combine the extracts, remove ethanol under reduced pressure to obtain 903g of total extract, petroleum ether, ethyl acetate in turn Equivalent extraction, the ethyl acetate extract was subjected to silica gel column chromatography (CH 2 Cl 2 -MeOH (15:5) elution), gel column chromatography (CHCl 3 -MeOH (1:1) elution) to get demethylwedelolactone (Demethylwedelolctone). The physical and chemical properties and spectral data are as follows: light yellow needle crystal (methanol). mp.≥360°C. Spray 1% AlCl 3 Ethanol liquid, blue fluorescence...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to application of demethylwedelolactone serving as medicine for resisting pulmonary fibrosis. The demethylwedelolactone is obtained from herba ecliptae, and the structure of the demethylwedelolactone is determined through spectrum data. When the demethylwedelolactone is used through intragastric administration, the pulmonary fibrosis degree of a model mouse is improved evidently, the MDA content reflecting lung injury degree is lowered, the HYP content reflecting lung tissue collagen deposition is reduced, the cell factor TGF-beta1 content causing the pulmonary fibrosis is reduced, and accordingly the pharmacological effect of improving the pulmonary fibrosis degree is brought into play, and human embryonic lung fibroblast proliferation and collagen generation are inhibited in vitro; in-vitro experiments prove that the demethylwedelolactone evidently improves the mouse pulmonary fibrosis induced by bleomycin and can be used as new medicine for treating or improving the pulmonary fibrosis.

Description

technical field [0001] The invention relates to a new use of a monomer substance norwedelolide as a medicine for treating pulmonary fibrosis. Background technique [0002] Pulmonary fibrosis is a progressive disease characterized by fibrosis and lung parenchymal remodeling. Pulmonary fibroblasts hyperproliferate, transdifferentiate into myofibroblasts, secrete a large amount of collagen and deposit matrix. There is no effective treatment. The animal model of pulmonary fibrosis induced by bleomycin is the most commonly used. Tracheal administration of bleomycin can cause inflammation and fibrosis of lung tissue in a short period of time. Symptoms of fibrosis begin to appear 9 days after the model is established. symptoms of fibrosis [1] . [0003] Demethyledelolactone (Demethyledelolactone) is prepared from the medicinal plant Ecliptaprostrata L., literature [3-5] Studies have reported that norwedelolide is Na + / K + / ATPase inhibitor [6,7,8] , with liver protection, a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/366A61P11/00
CPCA61K31/366
Inventor 张朝凤陶丽君尤心怡张勉
Owner 张朝凤
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products